April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Randomized, Double-Masked, Controlled Translational Investigation Of Bevacizumab For Retinal Detachment Due To Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • Elliott H. Sohn
    University of Iowa, Iowa City, Iowa
    LA County Hospital + Doheny Eye Institute / USC, Los Angeles, California
  • Dean Eliott
    LA County Hospital + Doheny Eye Institute / USC, Los Angeles, California
  • Shikun He
    Doheny Eye Institute / USC, Los Angeles, California
  • Leo Kim
    LA County Hospital + Doheny Eye Institute / USC, Los Angeles, California
  • Hani Salehi-Had
    LA County Hospital + Doheny Eye Institute / USC, Los Angeles, California
  • Michael Javaheri
    LA County Hospital + Doheny Eye Institute / USC, Los Angeles, California
  • Chris Spee
    Doheny Eye Institute / USC, Los Angeles, California
  • Laurie Dustin
    Doheny Eye Institute / USC, Los Angeles, California
  • David Hinton
    Doheny Eye Institute / USC, Los Angeles, California
  • Footnotes
    Commercial Relationships  Elliott H. Sohn, None; Dean Eliott, None; Shikun He, None; Leo Kim, None; Hani Salehi-Had, None; Michael Javaheri, None; Chris Spee, None; Laurie Dustin, None; David Hinton, None
  • Footnotes
    Support  NEI Grant EY03040
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 981. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elliott H. Sohn, Dean Eliott, Shikun He, Leo Kim, Hani Salehi-Had, Michael Javaheri, Chris Spee, Laurie Dustin, David Hinton; Randomized, Double-Masked, Controlled Translational Investigation Of Bevacizumab For Retinal Detachment Due To Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):981. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The exact mechanisms underlying the pathogenesis of retinal detachment (RD) in proliferative diabetic retinopathy (PDR) are unclear. Connective tissue growth factor (CTGF) is a mediator of intraocular fibrosis and increased in eyes with active PDR. The purpose of this study was to assess the effect of VEGF inhibition on CTGF and VEGF in patients with diabetic RD.

Methods: : 20 eyes of 19 patients were randomized prospectively to receive intravitreal bevacizumab or sham injection 3-7 days prior to vitrectomy by a single surgeon for RD due to PDR. Patients with dense vitreous hemorrhage were excluded. Patient and surgeon were masked to treatment. RDs were graded as traction RD (TRD; mild, moderate, severe) or combined traction-rhegmatogenous RD (TRD/RRD). Fundus photos and SD-OCT were obtained at time of injection and on the day of surgery. Aqueous samples prior to injection and at time of surgery were collected. Vitreous samples and fibrovascular membranes were also collected. ELISA for VEGF and CTGF were performed on aqueous and vitreous samples. Statistical analysis of growth factor levels was done.

Results: : 5 eyes had moderate TRD, 8 had severe TRD, and 7 had combined TRD/RRD. 5 eyes had decreased vascularization of membranes from pre-injection to time of surgery (all in treatment arm) and only 1 of these had severe intra-operative bleeding.Median vitreous levels of VEGF were lower in the bevacizumab group than the control group (p-value=0.03). Median vitreous levels of CTGF (pg/mL) were 980 in the bevacizumab group and 1235 in the control group (p-value=0.38). CTGF levels in the aqueous were strongly correlated to those in the vitreous of controls (Spearman correlation coefficient 0.95, p-value<0.001). Correlation between VEGF and CTGF levels in the vitreous of the bevacizumab group was significant (p-value=0.01) and not observed in the control group. Clinical correlation to these laboratory findings is currently underway.

Conclusions: : Intravitreal bevacizumab administered within 3-7 days of surgery in patients with RD due to PDR effectively reduces vitreous levels of VEGF that produces a clinically observable alteration in fibrovascular membranes. Aqueous CTGF is a useful surrogate marker for vitreous CTGF in these eyes. There is a positive correlation between CTGF and VEGF levels in eyes treated with VEGF inhibition.

Clinical Trial: : http://www.clinicaltrials.gov USC-HS-09-00068

Keywords: diabetic retinopathy • retinal detachment • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×